Filing Details

Accession Number:
0001061983-17-000059
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-10-04 18:53:52
Reporting Period:
2017-10-02
Accepted Time:
2017-10-04 18:53:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1061983 Cytokinetics Inc CYTK Pharmaceutical Preparations (2834) 943291317
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1196903 Patrick L Gage 280 East Grand Avenue
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-10-02 5,000 $4.02 35,000 No 4 M Direct
Common Stock Disposition 2017-10-02 400 $14.40 34,600 No 4 S Direct
Common Stock Disposition 2017-10-02 600 $14.45 34,000 No 4 S Direct
Common Stock Disposition 2017-10-02 810 $14.55 33,190 No 4 S Direct
Common Stock Disposition 2017-10-02 300 $14.60 32,890 No 4 S Direct
Common Stock Disposition 2017-10-02 2,490 $14.65 30,400 No 4 S Direct
Common Stock Disposition 2017-10-02 400 $14.68 30,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2017-10-02 5,000 $0.00 5,000 $4.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
22,302 2013-02-02 2023-01-02 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,850 Indirect by Spouse
Footnotes
  1. The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017.
  2. The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017.